disorder

(redirected from Myeloproliferative disorders)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.

disorder

a disturbance of public order or peace. Its existence may trigger extended police powers.
References in periodicals archive ?
Elliott, "Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F," Seminars in Thrombosis and Hemostasis, vol.
Burgstaller et al., "Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders," Blood, vol.
Since patient had past history of myeloproliferative disorder and US scan revealed an enlarged liver we organised a CT scan abdomen and pelvis liver protocol.
According to Dameshek, true polycythemia (polycythemia vera: PV) is a chronic myeloproliferative disorder of the total bone marrow without any evidence of invasiveness, in which erythrocytosis, leukocytosis, and thrombocytosis are all simultaneously present.
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111: 1686-9.
The most common causes of thrombophilia in patients with BCS are JAK2 mutation positive myeloproliferative disorders (40%), followed by factor V Leiden (6.8-31.8%) mutation and prothrombin G20210A mutation (0-.64%).
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer.
18% of men in a cohort of patients seen at the center for myeloproliferative disorders of Johns Hopkins University in Baltimore, said Dr.
However, at least in patients with idiopathic myelofibrosis and other chronic myeloproliferative disorders, an alternative pathogenesis has been proposed.
Chronic myeloproliferative disorders (CMPDs) are clonal haematopoietic stem cell disorders and include the BCR-ABL negative CMPDs like polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myelofibrosis (IMF) and chronic eosinophilic leukaemia (CEL) (1,2).
Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009.
In these cases haemorrhage was associated with risk factors (myeloproliferative disorders, aspirin, platelet dysfunction, thrombocytopenia, obesity and disseminated intravascular coagulation) and the patients required sustained blood transfusion.